---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-015851"
form_type: "8-K"
ticker: "ESLA"
cik: "0001844417"
company_name: "Estrella Immunopharma, Inc."
filed_at: "2025-02-21T23:59:59+00:00"
generated_at: "2026-05-26T07:10:15.151118+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Estrella Immunopharma completes first dose cohort in STARLIGHT-1; DSMB approves second dose

## Summary
- First cohort enrolled relapsed/refractory B-cell NHL patients who failed multiple prior therapies; no DLTs or SAEs.
- DSMB approved escalation to second cohort at 5 million receptor-positive T cells/kg of EB103 therapy.
- Preliminary data showed tumor responses in all patients at Month 1; favorable safety profile.
- STARLIGHT-1 is an open-label, multi-center 3+3 dose-escalation study to determine RP2D for EB103.

## SEC filing metadata
- accession: 0001213900-25-015851
- form_type: 8-K
- ticker: ESLA
- cik: 0001844417
- company_name: Estrella Immunopharma, Inc.
- filed_at: 2025-02-21T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1844417/000121390025015851/0001213900-25-015851-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1844417/000121390025015851/ea023173701-8k_estrella.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-015851
- JSON: https://secwatch.observer/filing/0001213900-25-015851.json
- Plain text: https://secwatch.observer/filing/0001213900-25-015851.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.